Key facts
- Sable Biotechnology’s last known valuation is $17.2M (Feb 2026).
- It has raised $5.8M; the latest was Seed Round ($3.9M) in Feb 2026.
- Notable investors include Seedcamp, MMC Ventures, CAS (Columbus), Episode 1 Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Sable Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Sable Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sable Biotechnology
Developer of a biomedical data platform designed to provide drug safety insights. The company's platform leverages artificial intelligence and large language models to generate proprietary datasets and extract data from unstructured trial reports, enabling the pharmaceutical industry to reduce the cost and time taken to produce toxicology drug safety reports.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2023
- Employees
- 3
- Website
- sablebio.com/
- Ownership
- Privately Held (backing)
Sable Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sable Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sable Biotechnology in its N-PORT filings yet. We sweep new filings monthly.